

Pharmacy and Therapeutics Committee (Virtual Meeting)

October 14, 2020

12:00pm - 5:00pm

Zoom Meeting Registration:

https://ahcccs.zoom.us/webinar/register/WN_t7iF3Vv9QNGnRmUJ7bfqEw

Time	Topic
12:00 PM	Welcome and Introductions: Suzi Berman, RPh, Director of Pharmacy, AHCCCS <ul style="list-style-type: none"> • May 19, 2020 - P&T Minutes Review and Vote
12:15 PM	Non-Supplemental Rebate Class Review: Clinical review by Justin Johnson, PharmD, Magellan <ol style="list-style-type: none"> 1. Antimigraine Agents - Triptans <ol style="list-style-type: none"> a. Public Testimony: None 2. Leukotriene Modifiers Oral Agents <ol style="list-style-type: none"> a. Public Testimony: None 3. Phosphate Binders <ol style="list-style-type: none"> a. Public Testimony: None 4. Sedative Hypnotics <ol style="list-style-type: none"> a. Public Testimony: None 5. Antifungals – Oral Agents <ol style="list-style-type: none"> a. Public Testimony: None 6. Antifungals - Topicals <ol style="list-style-type: none"> a. Public Testimony: None 7. Beta Blockers <ol style="list-style-type: none"> a. Public Testimony: None 8. BPH Treatments <ol style="list-style-type: none"> a. Public Testimony: None 9. Calcium Channel Blockers <ol style="list-style-type: none"> a. Public Testimony: None 10. Contraceptives – Oral Agents <ol style="list-style-type: none"> a. Public Testimony: None 11. Contraceptives - Other <ol style="list-style-type: none"> a. Public Testimony: None

	<p>12. Bladder Relaxant Preparations a. Public Testimony: None</p> <p>13. Antiparkinsons Agents a. Public Testimony: None</p> <p>14. Lipotropics - Statins a. Public Testimony: None</p> <p>15. Lipotropics - Other a. Public Testimony: None</p> <p>16. Proton Pump Inhibitors a. Public Testimony: None</p> <p>17. Acne Agents - Topicals a. Public Testimony: None</p>						
1:30 PM	<p>New Drug Reviews: Justin Johnson, PharmD, Magellan</p> <table> <thead> <tr> <th><u>Brand Name</u></th> <th><u>Generic Name</u></th> </tr> </thead> <tbody> <tr> <td>1. Dayvigo</td> <td>leborexant</td> </tr> <tr> <td>2. Oriahnn</td> <td>elagolix/estradiol/norethindrone</td> </tr> </tbody> </table>	<u>Brand Name</u>	<u>Generic Name</u>	1. Dayvigo	leborexant	2. Oriahnn	elagolix/estradiol/norethindrone
<u>Brand Name</u>	<u>Generic Name</u>						
1. Dayvigo	leborexant						
2. Oriahnn	elagolix/estradiol/norethindrone						
2:00 PM	Break & Executive Session						
3:45 PM	Public Therapeutic Class Votes – Chris Andrews, PharmD, Magellan						
4:15 PM	<p>Biosimilar Update: Justin Johnson, PharmD, Magellan</p> <ol style="list-style-type: none"> 1. Avsola – infliximab-axxq 2. Herzuma – trastuzumab-pkrb 3. Ontruzant – trastuzumab-dttb 						
5:00 PM	<p>Meeting Adjournment</p> <p>Future Meeting Dates: January 26, 2021 May 19, 2021</p>						